ReviewHepatology forum2026
Occult hepatitis B infection.
Review in Hepatology forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Occult Hepatitis B Infection (OBI) is a condition in which HBsAg tests are negative, but Hepatitis B virus (HBV) DNA is detectable in the liver, with or without low levels of HBV DNA in the blood (<200 IU/mL). The Hepatitis B surface antigen (HBsAg) negative status in OBI may result from the absence or low production of HBsAg due to immune system defense mechanisms or mutations in the S genome of HBV DNA, which make HBsAg undetectable. The gold standard for diagnosing OBI is testing for HBV DNA from liver tissue, with an alternative method being HBV DNA testing from serum. Patients with OBI may be at risk of transmitting HBV to others through blood transfusions or organ transplants. Reactivation may occur, especially in OBI patients who are immunocompromised or undergoing immunosuppressive therapy. Antiviral prophylaxis may be considered for OBI patients at risk of reactivation. Additionally, OBI patients also carry a risk of developing hepatocellular carcinoma (HCC), similar to those with non-occult hepatitis B infection. Antiviral therapy for OBI is generally not required unless the case represents false OBI due to HBsAg mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.